Dr. Michaela Barbier

Weir, Kristie Rebecca, Tombez, Clémentine, Mattmann, Yvonne, Zambrano, Sofia C, Ferguson, Eliza, Jungo, Katharina Tabea, Zangger, Martina, Volken, Shana, Vallejo-Yagüe, Enriqueta, Lüthold, Renata Vidonscky, Schulthess-Lisibach, Angela Edith, Bieri, Christof, Barbier, Michaela, Pascal Juillerat, Pascal, Streit, Sven, & Inauen, Jennifer. (2025). Development of a deprescribing intervention for proton pump inhibitors in primary care: A co-design approach with general practitioners and patients. Basic and Clinical Pharmacology and Toxicology. https://doi.org/10.1111/bcpt.70091

Barbier, Michaela Carla, Galactionova, Katya, Lambiris, Mark, Oliveira, Leonel, Rüter, Florian, Glinz, Dominik, Thürmer, Jessica, Pletscher, Flurina, Kasenda, Benjamin, Finazzi, Tobias, König, David, Lardinois, Didier, Conrad, Larissa, Mutz, Leonie, & Schwenkglenks, Matthias. (2025). Contributing to a value-based health care framework for lung cancer patients in Switzerland – A methodological approach to merge routinely collected hospital data [Journal-article]. PLOS ONE, 20(7). https://doi.org/10.1371/journal.pone.0327814

Schulthess-Lisibach, Angela Edith, Lüthold, Renata Vidonscky, Tombez, Clémentine, Weir, Kristie Rebecca, Zangger, Martina, Chan, Samantha, Jenal, Flurina, Roumet, Marie, Mattmann, Yvonne, Bieri, Christof, Aubert, Carole Elodie, Rodondi, Nicolas, Zambrano Ramos, Sofia Carolina, Trelle, Sven, Neuner-Jehle, Stefan, Juillerat, Pascal, Barbier, Michaela, Inauen, Jennifer, Streit, Sven, et al. (2025). DepRescribing inapprOpriate Proton Pump InhibiTors (DROPIT): study protocol of a cluster-randomised controlled trial in Swiss primary care [Journal-article]. BMJ Open, 15(1), e094495. https://doi.org/10.1136/bmjopen-2024-094495

El Saadany, Tämer, Lupatsch, Judith, Mark, Michael, Barbier, Michaela, Mehra, Tarun, Schwenkglenks, Matthias, & Von Moos, Roger. (2025). A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRASG12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland [Journal-article]. Swiss Medical Weekly, 155(1). https://doi.org/10.57187/s.3777

Barbier, Michaela Carla, Fengler , Alicia, Pardo ,Esther, Bhadhuri , Arjun, Meier, Niklaus, & Gautschi, Oliver. (2023). Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland. PharmacoEconomics, 41(12), 1641–1655. https://doi.org/10.1007/s40273-023-01305-3

Finazzi, Tobias, Oliveira, Leonel, Mutz, Leonie, König, David, Kasenda, Benjamin, Lardinois Didier, Barbier, Michaela, Galactionova, Katya, Schwenkglenks, Matthias, Glinz, Dominik, Pletscher, Flurina, Rothschild, Sacha, & Rüter, Florian. (2023, January 1). Patient Reported Outcome Measures (PROMs) in a multidisciplinary lung cancer centre: a value-based healthcare pilot project. In SOCH. https://www.researchgate.net/publication/378675035_Patient_Reported_Outcome_Measures_PROMs_in_a_multidisciplinary_lung_cancer_centre_a_value-based_healthcare_pilot_project

Menges D, Yebyo HG, Sivec-Muniz S, Haile SR, Barbier MC, Tomonaga Y, Schwenkglenks M, & Puhan MA. (2022). Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment. European Urology Oncology, 5(6), 605–616. https://doi.org/10.1016/j.euo.2022.04.007

Barbier, Michaela C., Tomonaga, Yuki, Menges, Dominik, Yebyo, Henock G., Haile, Sarah R., Puhan, Milo A., & Schwenkglenks, Matthias. (2022). Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer. PLOS ONE, 17(11). https://doi.org/10.1371/journal.pone.0277282

Barbier, Michaela, Durno, Nicholas, Bennison, Craig, Örtli, Mathias, Knapp, Christian, & Schwenkglenks, Matthias. (2022). Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland. The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care, 23, 837–846. https://doi.org/10.1007/s10198-021-01398-7

Zgraggen, Armin, Stoffel, Sandro Tiziano, Barbier, Michaela Carla, & Marbet, Urs Albert. (2022). Colorectal cancer surveillance by colonoscopy in a prospective, population-based long-term Swiss screening study - outcomes, adherence, and costs. Zeitschrift Für Gastroenterologie, 60(05), 761–778. https://doi.org/10.1055/a-1796-2471

Barbier, Michaela Carla, Pardo, Esther, Panje, Cédric Michael, Gautschi, Oliver, Lupatsch, Judith Eva, & Swiss Group for Clinical Cancer Research (SAKK). (2021). A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. European Journal of Health Economics, 22(5), 669–677. https://doi.org/10.1007/s10198-021-01282-4

Panje, C. M., Lupatsch, J. E., Barbier, M., Pardo, E., Lorez, M., Dedes, K. J., Aebersold, D. M., Plasswilm, L., Gautschi, O., Schwenkglenks, M., & Swiss Group for Clinical Cancer Research,. (2020). A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. Annals of Oncology, 31(4), 501–506. https://doi.org/10.1016/j.annonc.2020.01.007

Barbier, Michaela, Tomonaga, Yuki, Schur, Nadine, Menges, Dominik, Schwenkglenks, Matthias, Schmucker, C, Titscher, V, Braun, C, Dobrescu, A, Klerings, I, Nussbaumer-Streit, B, Gartlehner, G, & Meerpohl, JJ. (2019). Swiss Medical Board HTA Assessment Report: Comparative effectiveness, safety, and costs of surgical versus non-surgical treatment in patients with full-thickness rotator cuff tears: a systematic review and health economic assessment. ECPM, University of Basel. https://www.swissmedicalboard.ch/fileadmin/public/news/2019/Assessment_Report_Rotator_cuff_tears_incl_Postscript_2019.pdf

Barbier, Michaela, Tomonaga, Yuki, & Schwenkglenks, Matthias. (2018). Swiss Medical Board HTA Assessment Report: Robot-assisted versus open surgery for radical prostatectomy and robot-assisted versus laparoscopic surgery for simple or radical hysterectomy. ECPM, University of Basel. https://www.swissmedicalboard.ch/fileadmin/public/news/2018/assessment_report_smb_robot-assisted_surgery_long_2018.pdf

Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, & Brunel P. (2009). Efficacy and safety of initial combination therapy with amlodipine/ valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: The EX-STAND study. Journal of Human Hypertension, 23(7), 479–489. https://doi.org/10.1038/jhh.2008.153

Allemann Y, Fraile B, Lambert M, Barbier M, Ferber P, & Izzo JL Jr. (2008). efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: The exforge in failure after single therapy (EX-FAST) study. Journal of Clinical Hypertension, 10(3), 185–194. https://doi.org/10.1111/j.1751-7176.2008.07516.x

Glasbrenner M, & Rosenkranz G. (2006). A note on ethnic sensitivity studies. Journal of Biopharmaceutical Statistics, 16(1), 15–23. https://doi.org/10.1080/10543400500406454